Personalized vascular medicine: Individualizing drug therapy

被引：15

作者：

deGoma, Emil M. ^{[1
]}

Rivera, Giovanni ^{[2
]}

Lilly, Scott M. ^{[1
]}

Usman, M. Haris U. ^{[1
]}

Mohler, Emile R., III ^{[1
]}

机构：

[1] Univ Penn, Div Cardiovasc Med, Philadelphia, PA 19104 USA

[2] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA

来源：

VASCULAR MEDICINE | 2011年 / 16卷 / 05期

关键词：

anticoagulants; antihypertensive agents; aspirin; statins; vascular diseases; warfarin; PERCUTANEOUS CORONARY INTERVENTION; BLOOD-PRESSURE RESPONSE; ACUTE MYOCARDIAL-INFARCTION; PRINC PLAVIX RESPONSE; CHRONIC HEART-FAILURE; ANTIPLATELET THERAPY; PLATELET INHIBITION; CARDIOVASCULAR RISK; ASPIRIN RESISTANCE; CHOLESTEROL CONCENTRATIONS;

D O I：

10.1177/1358863X11422251

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Personalized medicine refers to the application of an individual's biological fingerprint - the comprehensive dataset of unique biological information - to optimize medical care. While the principle itself is straightforward, its implementation remains challenging. Advances in pharmacogenomics as well as functional assays of vascular biology now permit improved characterization of an individual's response to medical therapy for vascular disease. This review describes novel strategies designed to permit tailoring of four major pharmacotherapeutic drug classes within vascular medicine: antiplatelet therapy, antihypertensive therapy, lipid-lowering therapy, and antithrombotic therapy. Translation to routine clinical practice awaits the results of ongoing randomized clinical trials comparing personalized approaches with standard of care management.

引用

页码：391 / 404

页数：14

共 115 条

[31] Renin-Guided Treatment of Hypertension: Time for Action [J].

Furberg, Curt D. .

AMERICAN JOURNAL OF HYPERTENSION, 2010, 23 (09) :929-930

[32] Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin [J].

Gage, B. F. ;

Eby, C. ;

Johnson, J. A. ;

Deych, E. ;

Rieder, M. J. ;

Ridker, P. M. ;

Milligan, P. E. ;

Grice, G. ;

Lenzini, P. ;

Rettie, A. E. ;

Aquilante, C. L. ;

Grosso, L. ;

Marsh, S. ;

Langaee, T. ;

Farnett, L. E. ;

Voora, D. ;

Veenstra, D. L. ;

Glynn, R. J. ;

Barrett, A. ;

McLeod, H. L. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (03) :326-331

[33] Effects of Polyunsaturated Omega-3 Fatty Acids on Responsiveness to Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention The OMEGA-PCI (OMEGA-3 Fatty Acids After PCI to Modify Responsiveness to Dual Antiplatelet Therapy) Study [J].

Gajos, Grzegorz ;

Rostoff, Pawel ;

Undas, Anetta ;

Piwowarska, Wieslawa .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (16) :1671-1678

[34] The role of aspirin in cardiovascular prevention - Implications of aspirin resistance [J].

Gasparyan, Armen Yuri ;

Watson, Timothy ;

Lip, Gregory Y. H. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (19) :1829-1843

[35] Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation [J].

Geisler, Tobias ;

Langer, Harald ;

Wydymus, Magdalena ;

Goehring, Katrin ;

Zuern, Christine ;

Bigalke, Boris ;

Stellos, Konstantinos ;

May, Andreas E. ;

Gawaz, Meinrad .

EUROPEAN HEART JOURNAL, 2006, 27 (20) :2420-2425

[36] The genetics of statin-induced myopathy [J].

Ghatak, Abhijit ;

Faheem, Osman ;

Thompson, Paul D. .

ATHEROSCLEROSIS, 2010, 210 (02) :337-343

[37]

Ginsberg HN, 2010, NEW ENGL J MED, V362, P1563, DOI 10.1056/NEJMoa1001282

[38] The Antiplatelet Effect of Higher Loading and Maintenance Dose Regimens of Clopidogrel The PRINC (Plavix Response in Coronary Intervention) Trial [J].

Gladding, Patrick ;

Webster, Mark ;

Zeng, Irene ;

Farrell, Helen ;

Stewart, Jim ;

Ruygrok, Peter ;

Ormiston, John ;

El-Jack, Seif ;

Armstrong, Guy ;

Kay, Patrick ;

Scott, Douglas ;

Gunes, Arzu ;

Dahl, Marja-Liisa .

JACC-CARDIOVASCULAR INTERVENTIONS, 2008, 1 (06) :612-619

[39] The Pharmacogenetics and Pharmacodynamics of Clopidogrel Response An Analysis From the PRINC (Plavix Response in Coronary Intervention) Trial [J].

Gladding, Patrick ;

Webster, Mark ;

Zeng, Irene ;

Farrell, Helen ;

Stewart, Jim ;

Ruygrok, Peter ;

Ormiston, John ;

El-Jack, Seif ;

Armstrong, Guy ;

Kay, Patrick ;

Scott, Douglas ;

Gunes, Arzu ;

Dahl, Marja-Liisa .

JACC-CARDIOVASCULAR INTERVENTIONS, 2008, 1 (06) :620-627

[40] Rosuvastatin 5 and 10 mg/d: A pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies [J].

Glueck, Charles J. ;

Aregawi, Dawit ;

Agloria, Mahlia ;

Khalil, Qasim ;

Winiarska, Magdalena ;

Munjal, Jitender ;

Gogineni, Srikanth ;

Wang, Ping .

CLINICAL THERAPEUTICS, 2006, 28 (06) :933-942

← 1 2 3 4 5 6 7 8 9 10 →